Previous 10 | Next 10 |
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment o...
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta,...
While risk is always involved when investing in stocks, some equities are riskier than others. For instance, small-cap companies -- that is, those with market caps between $300 million and $2 billion -- tend to carry above-average risk. However, these companies can also offer substantia...
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, ...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) , a biopharmaceutical company that specializes in neuroscience and immuno-oncology therapies, saw its shares rise 25.2% this week, according to data from S&P Global Market Intelligence . The stock closed last Friday at $11.74...
BioXcel begins a new stage with IGALMI in the commercialization process. With a current market cap of just $300 million, I think BioXcel offers an excellent investment opportunity right now. I believe that BioXcel could reach a capitalization of between $1 billion and $1.5 billion...
BioXcel Therapeutics Inc. (BTAI) Q1 2022 Earnings Conference Call May 9, 2022 8:30 am ET Company Participants Vimal Mehta - Chief Executive Officer Matt Wiley - Chief Commercial Officer Richard Steinhart - Vice President, Chief Financial Officer Rob Risinger - Chief Medical Officer, Neuroscie...
BioXcel Therapeutics (NASDAQ:BTAI) stock fell May 9 after the company reported its Q1 results. Net loss widened to -$31.47M, compared to -$26.38M in Q1 2021. Research and development expenses increased to $18.56M, compared to $14.74M in Q1 2021. The company said the increase was mainly due to...
BioXcel Therapeutics press release (NASDAQ:BTAI): Q1 GAAP EPS of -$1.12 beats by $0.01. Cash and cash equivalents of $200.43M For further details see: BioXcel Therapeutics GAAP EPS of -$1.12 beats by $0.01
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acut...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...